Core Viewpoint - Rubico Inc. has announced an agreement to acquire 100% of a Marshall Islands company that is a counterparty to a shipbuilding contract for a new medium-range oil tanker, with delivery scheduled for 2029 [1][2]. Group 1: Acquisition Details - The acquisition involves a purchase price of approximately $4.2 million for the shares of the Special Purpose Vehicle (SPV) [4]. - The transaction was approved by a special committee of independent board members, and a fairness opinion was obtained from an independent financial advisor [4]. Group 2: Financing Arrangements - The effectiveness of the shipbuilding contract is contingent upon the issuance of a customary refund guarantee and the conclusion of financing arrangements [2]. - The SPV is finalizing a lease financing agreement with ABC Financial Leasing Co., Ltd., which will cover the majority of the shipbuilding contract's price [2]. Group 3: Revenue Potential - A time charter employment has been secured with a major oil trader for the vessel, starting from its delivery for a firm duration of seven years, with an option to extend for four additional years [3]. - The total potential gross revenue backlog from this charter contract, including optional years, is estimated to be around $75 million [3]. Group 4: Company Overview - Rubico Inc. is a global provider of shipping transportation services, specializing in vessel ownership and operation [5]. - The company operates two modern, fuel-efficient Suezmax tankers and is incorporated in the Marshall Islands with executive offices in Athens, Greece [5].

Core Insights - T3 Defense Inc. has announced two senior leadership appointments to enhance execution, scalability, and long-term production reliability in the Aerospace and Defense sector [1][2] Leadership Appointments - Emil Blumer has been appointed as Chief Business Officer, responsible for growth strategy, deal flow, and market positioning, bringing over 25 years of defense industry experience [3][4] - Jordan Buchler has been appointed as Chief Executive Officer of the Manufacturing & Industrial Processing Division, focusing on expanding manufacturing throughput and standardizing processes [5][6] Experience and Responsibilities - Mr. Blumer's experience includes senior roles at Rafael Advanced Defense Systems, where he gained insights into industrial capacity and supplier readiness, which will inform T3 Defense's commercial strategy [3][4] - Mr. Buchler has over 20 years of experience in building operational systems in constrained environments, with a focus on identifying critical paths and expanding capacity in defense manufacturing [6][7] Strategic Focus - The leadership changes signal T3 Defense's commitment to enhancing the most constrained layers of the defense supply chain, operating as a federated holding company to align commercial and operational leadership [7][9] - The company aims to convert durable backlogs into repeatable production output, addressing the limitations in the industrial base that affect defense output [8][9] Company Overview - T3 Defense Inc. is a federated holding company focused on acquiring and operating mission-critical defense businesses within long-cycle national security programs, targeting areas where strategic value and execution are critical [9]

Head Office : 4 allée de l'Arche, 92400 Courbevoie, FranceTel : + 33 (0) 1 78 15 00 00 – www.nexans.coma French Société Anonyme with a share capital of € 43,744,779 – R.C.S. Nanterre 393 525 852 – Id VAT FR 74 393 525 852 Disclosure of trading in own shares From February 16, 2026 to February 20, 2026 Issuer : Nexans Category : treasury shares Pursuant to applicable law on share buybacks, Nexans declares the following purchases of its own shares from F ...

Group 1: Kraig Biocraft Laboratories - Kraig Biocraft Laboratories' recombinant spider silk technology has gained significant visibility by being featured on the cover of National Geographic's March 2026 issue, which could lead to increased investor interest [2][4] - The company is set to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam, aiming for a production target of up to 10 metric tons of cocoons per month starting in March 2026 [5] - Scientific validation published in the Proceedings of the National Academy of Sciences confirms that Kraig's fibers are tougher than conventional silk and comparable to native spider dragline silk [5] - If successful, Kraig could become the second company to achieve sustained commercial production from a transgenic animal platform, a milestone previously associated with ATryn [6] - Investors are closely monitoring for initial deliveries to global brand partners in luxury fashion and performance sportswear, which could transition Kraig from a research-focused entity to a specialty materials platform [8] Group 2: Gilead Sciences and Arcellx - Gilead Sciences has announced a definitive agreement to acquire Arcellx for $115 per share in cash, plus a $5 contingent value right, representing an implied equity value of approximately $7.8 billion [9] - The acquisition provides Gilead with full control of anitocabtagene autoleucel, a CAR T-cell therapy for multiple myeloma, with the FDA accepting the BLA and a PDUFA action date set for December 23, 2026 [10] - Gilead's CEO emphasized the potential of anito-cel to become a foundational treatment for multiple myeloma and its importance in enhancing Gilead's oncology and inflammation capabilities [11] Group 3: ImmunityBio - ImmunityBio reported approximately $113 million in net product revenue for ANKTIVA in 2025, reflecting a 700% year-over-year growth [13] - The company also experienced a 750% increase in unit sales volume and expanded regulatory authorization across 33 countries [13] - ImmunityBio is positioning ANKTIVA as a backbone immunotherapy platform with ongoing randomized trials and long-term patent protection extending beyond 2035 [15] Group 4: Getty Images and Shutterstock - Getty Images and Shutterstock received unconditional antitrust clearance from the U.S. Department of Justice for their proposed merger, which aims to strengthen their financial foundation and competitive positioning in the visual content market [16][17]

Core Insights - LiveOne has launched its award-winning app on VIZIO smart TVs, providing users with free 24/7 access to its music service [1][2] - The app enhances LiveOne's distribution, reaching over 1.3 billion monthly active users across various platforms [4] Company Overview - LiveOne is a creator-first music, entertainment, and technology platform headquartered in Los Angeles, CA, focusing on delivering premium experiences through memberships and live events [2] - The company operates several subsidiaries, including Slacker, PodcastOne, and LiveXLive, and offers its services across multiple devices and platforms [2] Product Features - The LiveOne app allows users to listen to hundreds of curated music stations across more than 30 genres and create custom stations based on their preferences [5] - Users receive personalized recommendations for music and podcasts, access popular podcast shows, and can watch live streaming performances and interviews [5] - The app also offers curated video content and subscription tiers that provide additional features such as ad-free listening and offline playback [5] Strategic Partnerships - LiveOne anticipates forming at least two additional Fortune 250 B2B partnerships by the end of the year, further expanding its market reach [4]

Core Viewpoint - INmune Bio Inc. is advancing its clinical development of XPro1595 for early Alzheimer's disease, with a webinar scheduled to discuss the registrational pathway and recent trial results [1][2]. Group 1: Clinical Development - The Phase 2 MINDFuL trial has been completed, and feedback from the FDA supports moving to a registrational study for Alzheimer's patients with inflammation biomarkers [2]. - XPro1595 is a next-generation selective soluble TNF inhibitor aimed at restoring immune homeostasis in the brain without affecting transmembrane TNF or TNF receptors [3][10]. Group 2: Webinar Details - The webinar will cover three main topics: results from the MINDFuL trial, the design of the registrational study, and the strategic roadmap to Phase 3, including global partnership opportunities [3][4][5]. - Featured speakers include Dr. Michael Woodward and Dr. Sharon Cohen, both recognized experts in Alzheimer's disease research [6]. Group 3: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms: CORDStrom™, XPro™, and INKmune® [11].

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, highlighting the company's strategic focus on value-generating transactions and advancements in their product pipeline [1][3]. Company Developments - Cyprium Therapeutics has transferred the development and commercialization rights of ZYCUBO to Sentynl Therapeutics, which was approved by the FDA on January 12, 2026, for treating Menkes disease [2]. - The PRV was issued following the FDA approval of ZYCUBO, and Cyprium is set to receive tiered royalties on net sales and up to $129 million in development and sales milestones from Sentynl [2]. - Cyprium is obligated to pay 20% of the PRV sale proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development [2]. Strategic Positioning - Fortress Biotech's Chairman emphasized the significance of the PRV sale and recent FDA approvals for their products, indicating a strong position to execute on their portfolio [3]. - Cyprium's recent achievements include the approval of ZYCUBO and the execution of the asset sale, with plans to advance AAV-ATP7A Gene Therapy for Menkes disease [3]. Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development for clinical development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed products and multiple development programs across various therapeutic areas [5].

Group 1 - Century Aluminum Company will have its President and CEO, Jesse Gary, present at the BMO Global Metals, Mining, & Critical Minerals Conference on February 24, 2026, at 8:15 a.m. EST [1] - A real-time audio webcast of the conference session will be accessible on the "Investors" section of Century's website [1] Group 2 - Century Aluminum Company is headquartered in Chicago, IL, and operates primary aluminum smelting facilities in the United States and Iceland [2] - The company is the majority owner and managing partner of the Jamalco alumina refinery located in Jamaica [2]

Core Insights - Algorhythm Holdings, Inc. has secured an additional $9.5 million under its existing $20 million financing facility, raising the total capital to $19.5 million, which positions the company to execute its global growth strategy for the SemiCab platform [1][2] Financial Position - Following the new funding, Algorhythm reported approximately $12.5 million in cash on hand, providing sufficient capital for the expansion of its SemiCab platform in India, the U.S., and other international markets [2] - The company has repaid approximately $7 million of the initial $10 million under the financing facility, enhancing its balance sheet and increasing stockholders' equity [3] Strategic Focus - The company aims to utilize the proceeds from the funding to accelerate U.S. go-to-market efforts for the newly launched SemiCab Apex SaaS platform, grow its customer base in India, expand into new freight logistics markets, and develop complementary products and services [6] Company Overview - Algorhythm Holdings, Inc. is a leading AI technology company focused on the growth of SemiCab, which addresses supply-chain challenges globally through its AI-enabled, cloud-based Collaborative Transportation Platform [4] - SemiCab's platform utilizes real-time data and advanced predictive optimization models to enhance logistics efficiency, allowing shippers to reduce costs while increasing carrier earnings [4]

Core Viewpoint - Tian Ruixiang Holdings Ltd is in advanced discussions for a strategic business combination with a leading InsurTech company in the Asia-Pacific region, alongside its ongoing Bitcoin acquisition strategy aimed at enhancing shareholder value [1][2][6]. Group 1: Strategic Business Combination - The InsurTech leader is characterized as a well-capitalized, high-growth entity with proprietary AI-driven underwriting, digital distribution, and automated claims processing [3]. - The proposed structure will position Tian Ruixiang as the exclusive public platform for the InsurTech to access U.S. capital markets, facilitating its global expansion [4]. - Existing shareholders of TIRX will maintain full public market ownership and benefit from the potential upside of the combined InsurTech platform [4][9]. Group 2: Shareholder Value Creation - The strategic initiatives are expected to attract significant institutional interest, expand analyst coverage, and create substantial shareholder value [5][9]. - The CEO emphasized that these initiatives represent a historic opportunity to unlock exceptional and sustainable value for shareholders, although no definitive agreement has been reached yet [6][7]. Group 3: Company Overview - Tian Ruixiang Holdings Ltd is a NASDAQ-listed holding company focused on insurance-related services in China, with a commitment to strategic transformation and maximizing long-term shareholder value [7].